miRNA‑22‑3p inhibits cell viability and metastasis of nasopharyngeal carcinoma by targeting FOXP1

Jin,Ying; Wang,Zhijun; Liang,Yuanshan; Jiang,Yiting; Yuan,Fayang; Zhang,Tian

doi:10.3892/ol.2024.14842

miRNA‑22‑3p inhibits cell viability and metastasis of nasopharyngeal carcinoma by targeting FOXP1

Authors:
- Ying Jin
- Zhijun Wang
- Yuanshan Liang
- Yiting Jiang
- Fayang Yuan
- Tian Zhang
View Affiliations

Affiliations: Department of Otorhinolaryngology Head and Neck Surgery, Affiliated Hospital of Guizhou Medical University, Guiyang, Guizhou 550004, P.R. China
Published online on: December 10, 2024 https://doi.org/10.3892/ol.2024.14842
Article Number: 96
Copyright: © Jin et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nasopharyngeal carcinoma (NPC) is a malignant tumor with a high incidence rate in certain regions. MicroRNA (miRNA/miR)‑22‑3p is implicated in the regulation of tumorigenesis and progression. However, the biological role of miRNA‑22‑3p in the progression of NPC remains unclear. The present study aimed to assess the effects of miRNA‑22‑3p overexpression on the cell viability and migration of NPC cells. The cell viability and migration of HK‑1 cells was evaluated using Transwell, wound healing and Cell Counting Kit‑8 assays. To assess the epithelial‑mesenchymal transition ability of NPC cells, the expression of E‑cadherin, vimentin and N‑cadherin was evaluated using western blot analysis. The results revealed expression of miRNA‑22‑3p was significantly decreased in NPC tissues compared with para‑cancerous tissues. Decreased expression of miRNA‑22‑3p was also observed in NPC cell lines (C666‑1 and HK‑1). The overexpression of miRNA‑22‑3p reduced HK‑1 cell viability and migration. In addition, a dual luciferase reporter assay revealed that miRNA‑22‑3p functioned as a molecular sponge for forkhead box protein 1 (FOXP1). Notably, FOXP1 overexpression counteracted the suppressive effects induced by transfection with miRNA‑22‑3p mimic on HK‑1 cell viability and migration. Therefore, these data indicate that miRNA‑22‑3p may be a clinically valuable biomarker for the therapy of NPC.

View Figures

View References

1	Chen YP, Chan ATC, Le QT, Blanchard P, Sun Y and Ma J: Nasopharyngeal carcinoma. Lancet. 394:64–80. 2019. View Article : Google Scholar : PubMed/NCBI
2	Chang ET, Ye W, Zeng YX and Adami HO: The evolving epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 30:1035–1047. 2021. View Article : Google Scholar : PubMed/NCBI
3	Chua MLK, Lee VHF and Lee AWM: Hyperfractionation for reirradiation of recurrent nasopharyngeal carcinoma. Lancet. 401:878–879. 2023. View Article : Google Scholar : PubMed/NCBI
4	Guan S, Wei J, Huang L and Wu L: Chemotherapy and chemo-resistance in nasopharyngeal carcinoma. Eur J Med Chem. 207:1127582020. View Article : Google Scholar : PubMed/NCBI
5	Saliminejad K, Khorram Khorshid HR, Soleymani Fard S and Ghaffari SH: An overview of microRNAs: Biology, functions, therapeutics, and analysis methods. J Cell Physiol. 234:5451–5465. 2019. View Article : Google Scholar : PubMed/NCBI
6	Chekulaeva M: First demonstration of miRNA-dependent mRNA decay. Nat Rev Mol Cell Biol. 24:1642023. View Article : Google Scholar : PubMed/NCBI
7	Djuranovic S, Nahvi A and Green R: A parsimonious model for gene regulation by miRNAs. Science. 331:550–553. 2011. View Article : Google Scholar : PubMed/NCBI
8	Pozniak T, Shcharbin D and Bryszewska M: Circulating microRNAs in medicine. Int J Mol Sci. 23:39962022. View Article : Google Scholar : PubMed/NCBI
9	Ruggieri F, Jonas K, Ferracin M, Dengler M, Jӓger V and Pichler M: MicroRNAs as regulators of tumor metabolism. Endocr Relat Cancer. 30:e2202672023. View Article : Google Scholar : PubMed/NCBI
10	Zhu Q, Zhang Q, Gu M, Zhang K, Xia T, Zhang S, Chen W, Yin H, Yao H, Fan Y, et al: MIR106A-5p upregulation suppresses autophagy and accelerates malignant phenotype in nasopharyngeal carcinoma. Autophagy. 17:1667–1683. 2021. View Article : Google Scholar : PubMed/NCBI
11	Yin W, Shi L and Mao Y: MiR-194 regulates nasopharyngeal carcinoma progression by modulating MAP3K3 expression. FEBS Open Bio. 9:43–52. 2018. View Article : Google Scholar : PubMed/NCBI
12	Kong D, Wang X, Wang X, Wang Z and Wang F: Downregulated miRNA-22-3p promotes the progression and leads to poor prognosis of hepatocellular carcinoma through targeting CDKN2C. J BUON. 26:409–417. 2021.PubMed/NCBI
13	Barut Z and Akdeniz FT: Evaluation of the relationship between miRNA-22-3p and Gal-9 levels in glioblastoma. In Vivo. 37:2577–2584. 2023. View Article : Google Scholar : PubMed/NCBI
14	Li C, Li X, Wang H, Guo X, Xue J, Wang X and Ni J: MicroRNA-22-3p and MicroRNA-149-5p inhibit human hepatocellular carcinoma cell growth and metastasis properties by regulating methylenetetrahydrofolate reductase. Curr Issues Mol Biol. 44:952–962. 2022. View Article : Google Scholar : PubMed/NCBI
15	Koon HB, Ippolito GC, Banham AH and Tucker PW: FOXP1: A potential therapeutic target in cancer. Expert Opin Ther Targets. 11:955–965. 2007. View Article : Google Scholar : PubMed/NCBI
16	Ijichi N, Ikeda K, Horie-Inoue K and Inoue S: FOXP1 and estrogen signaling in breast cancer. Vitam Horm. 93:203–212. 2013. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Chen L, Heikkinen L, Wang C, Yang Y, Sun H and Wong G: Trends in the development of miRNA bioinformatics tools. Brief Bioinform. 20:1836–1852. 2019. View Article : Google Scholar : PubMed/NCBI
19	Hill M and Tran N: miRNA interplay: Mechanisms and consequences in cancer. Dis Model Mech. 14:dmm0476622021. View Article : Google Scholar : PubMed/NCBI
20	He B, Zhao Z, Cai Q, Zhang Y, Zhang P, Shi S, Xie H, Peng X, Yin W, Tao Y and Wang X: miRNA-based biomarkers, therapies, and resistance in cancer. Int J Biol Sci. 16:2628–2647. 2020. View Article : Google Scholar : PubMed/NCBI
21	Zhao Y, Chen X, Jing M, Du H and Zeng Y: Expression of miRNA-146a in nasopharyngeal carcinoma is upregulated by Epstein-Barr virus latent membrane protein 1. Oncol Rep. 28:1237–1242. 2012. View Article : Google Scholar : PubMed/NCBI
22	Fan DC, Zhao YR, Qi H, Hou JX and Zhang TH: MiRNA-506 presents multiple tumor suppressor activities by targeting EZH2 in nasopharyngeal carcinoma. Auris Nasus Larynx. 47:632–642. 2020. View Article : Google Scholar : PubMed/NCBI
23	Jia X, Yang M, Hu W and Cai S: Overexpression of miRNA-22-3p attenuates osteoporosis by targeting MAPK14. Exp Ther Med. 22:6922021. View Article : Google Scholar : PubMed/NCBI
24	Huang SC, Wang M, Wu WB, Wang R, Cui J, Li W, Li ZL, Li W and Wang SM: Mir-22-3p inhibits arterial smooth muscle cell proliferation and migration and neointimal hyperplasia by targeting HMGB1 in arteriosclerosis obliterans. Cell Physiol Biochem. 42:2492–2506. 2017. View Article : Google Scholar : PubMed/NCBI
25	Tang Y, Jin X, Xiang Y, Chen Y, Shen CX, Zhang YC and Li YG: The lncRNA MALAT1 protects the endothelium against ox-LDL-induced dysfunction via upregulating the expression of the miR-22-3p target genes CXCR2 and AKT. FEBS Lett. 589:3189–3196. 2015. View Article : Google Scholar : PubMed/NCBI
26	Gorur A, Bayraktar R, Ivan C, Mokhlis HA, Bayraktar E, Kahraman N, Karakas D, Karamil S, Kabil NN, Kanlikilicer P, et al: ncRNA therapy with miRNA-22-3p suppresses the growth of triple-negative breast cancer. Mol Ther Nucleic Acids. 23:930–943. 2021. View Article : Google Scholar : PubMed/NCBI
27	Katoh M and Katoh M: Human FOX gene family (Review). Int J Oncol. 25:1495–1500. 2004.PubMed/NCBI
28	Golson ML and Kaestner KH: Fox transcription factors: From development to disease. Development. 143:4558–4570. 2016. View Article : Google Scholar : PubMed/NCBI
29	Patzelt T, Keppler SJ, Gorka O, Thoene S, Wartewig T, Reth M, Förster I, Lang R, Buchner M and Ruland J: Foxp1 controls mature B cell survival and the development of follicular and B-1 B cells. Proc Natl Acad Sci USA. 115:3120–3125. 2018. View Article : Google Scholar : PubMed/NCBI
30	Shi C, Sakuma M, Mooroka T, Liscoe A, Gao H, Croce KJ, Sharma A, Kaplan D, Greaves DR, Wang Y and Simon DI: Down-regulation of the forkhead transcription factor Foxp1 is required for monocyte differentiation and macrophage function. Blood. 112:4699–4711. 2008. View Article : Google Scholar : PubMed/NCBI
31	Fox SB, Brown P, Han C, Ashe S, Leek RD, Harris AL and Banham AH: Expression of the forkhead transcription factor FOXP1 is associated with estrogen receptor alpha and improved survival in primary human breast carcinomas. Clin Cancer Res. 10:3521–3527. 2004. View Article : Google Scholar : PubMed/NCBI
32	Feng J, Zhang X, Zhu H, Wang X, Ni S and Huang J: High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol. 138:230–235. 2012. View Article : Google Scholar : PubMed/NCBI
33	Zhang Y, Zhang S, Wang X, Liu J, Yang L, He S, Chen L and Huang J: Prognostic significance of FOXP1 as an oncogene in hepatocellular carcinoma. J Clin Pathol. 65:528–533. 2012. View Article : Google Scholar : PubMed/NCBI
34	Han SL, Wu XL, Wan L, Zeng QQ, Li JL and Liu Z: FOXP1 expression predicts polymorphic histology and poor prognosis in gastric mucosa-associated lymphoid tissue lymphomas. Dig Surg. 26:156–162. 2009. View Article : Google Scholar : PubMed/NCBI
35	Barrans SL, Fenton JAL, Banham A, Owen RG and Jack AS: Strong expression of FOXP1 identifies a distinct subset of diffuse large B-cell lymphoma (DLBCL) patients with poor outcome. Blood. 104:2933–2935. 2004. View Article : Google Scholar : PubMed/NCBI
36	van Keimpema M, Grüneberg LJ, Mokry M, van Boxtel R, Koster J, Coffer PJ, Pals ST and Spaargaren M: FOXP1 directly represses transcription of proapoptotic genes and cooperates with NF-κB to promote survival of human B cells. Blood. 124:3431–3440. 2014. View Article : Google Scholar : PubMed/NCBI
37	Gascoyne DM and Banham AH: The significance of FOXP1 in diffuse large B-cell lymphoma. Leuk Lymphoma. 58:1037–1051. 2017. View Article : Google Scholar : PubMed/NCBI
38	Walker MP, Stopford CM, Cederlund M, Fang F, Jahn C, Rabinowitz AD, Goldfarb D, Graham DM, Yan F, Deal AM, et al: FOXP1 potentiates Wnt/β-catenin signaling in diffuse large B cell lymphoma. Sci Signal. 8:ra122015. View Article : Google Scholar : PubMed/NCBI